Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.

Lupin Limited has received US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Genentech's Lucentis. Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States available in both vials and pre-filled syringes. The drug is approved in two strengths, 0.3mg and 0.5mg, for treating neovascular age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, diabetic retinopathy and myopic choroidal neovascularization. Ranibizumab is a recombinant humanised monoclonal antibody fragment that inhibits vascular endothelial growth factor A. This marks Lupin's second US biosimilar approval. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally and employs over 24,000 professionals across 15 manufacturing sites and seven research centres.